{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T17:15:34Z","timestamp":1781111734590,"version":"3.54.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T00:00:00Z","timestamp":1596499200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T00:00:00Z","timestamp":1596499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["P30 DA035772"],"award-info":[{"award-number":["P30 DA035772"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s11606-020-06073-w","type":"journal-article","created":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T05:02:40Z","timestamp":1596603760000},"page":"3262-3270","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Medication Utilization for Alcohol Use Disorder in a Commercially Insured Population"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1860-3956","authenticated-orcid":false,"given":"Haiden A.","family":"Huskamp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Reif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly F.","family":"Greenfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon-Lise T.","family":"Normand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisa B.","family":"Busch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,4]]},"reference":[{"key":"6073_CR1","unstructured":"Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results from the 2018 National Survey on Drug Use and Health. HHS Publication No. PEP19-5068, NSDUH Series H-54. Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Available at: https:\/\/www.samhsa.gov\/data\/. Accessed January 13, 2020."},{"key":"6073_CR2","unstructured":"Centers for Disease Control and Prevention. Alcohol and Public Health: Alcohol-Related Disease Impact (ARDI) \u2013 Average for United States 2006 2010 Alcohol-Attributable Deaths Due to Excessive Alcohol Use. Available at: www.cdc.gov\/ARDI. Accessed September 23, 2019."},{"key":"6073_CR3","unstructured":"Substance Abuse and Mental Health Services Administration. Results from the 2017 National Survey on Drug Use and Health: Detailed Tables. Available at: https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/cbhsq-reports\/NSDUHDetailedTabs2017\/NSDUHDetailedTabs2017.htm#tab5-12A. Accessed January 13, 2020."},{"issue":"1","key":"6073_CR4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/ADM.0b013e3181d41ddb","volume":"5","author":"HK Knudsen","year":"2011","unstructured":"Knudsen HK, Abraham AJ, Roman PM. Adoption and implementation of medications in addiction treatment programs. J Addict Med. 2011;5(1):21-27.","journal-title":"J Addict Med."},{"issue":"1-2","key":"6073_CR5","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.drugalcdep.2013.01.016","volume":"132","author":"T Iheanacho","year":"2013","unstructured":"Iheanacho T, Issa M, Marienfeld C, Rosenheck R. Use of naltrexone for alcohol use disorders in the Veterans' Health Administration: a national study. Drug Alcohol Depend. 2013;132(1-2):122-126","journal-title":"Drug Alcohol Depend."},{"issue":"1-3","key":"6073_CR6","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.drugalcdep.2008.07.018","volume":"99","author":"TL Mark","year":"2009","unstructured":"Mark TL, Kassed CA, Vandivort-Warren R, Levit KR, Kranzler HR. Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty. Drug Alcohol Depend. 2009;99(1-3):345-349.","journal-title":"Drug Alcohol Depend."},{"issue":"4","key":"6073_CR7","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1080\/08897077.2016.1189477","volume":"37","author":"T Rieckmann","year":"2016","unstructured":"Rieckmann T, Muench J, McBurnie MA, et al. Medication-assisted treatment for substance use disorders within a national community health center research network. Subst Abus. 2016;37(4):625-634","journal-title":"Subst Abus."},{"issue":"7","key":"6073_CR8","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1176\/appi.ps.201000553","volume":"63","author":"AH Harris","year":"2012","unstructured":"Harris AH, Oliva E, Bowe T, Humphreys KN, Kivlahan DR, Trafton JA. Pharmacotherapy of alcohol use disorders by the Veterans Health Administration: patterns of receipt and persistence. Psychiatr Serv. 2012;63(7):679-685","journal-title":"Psychiatr Serv."},{"issue":"1","key":"6073_CR9","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1080\/08897077.2015.1028699","volume":"37","author":"HK Knudsen","year":"2016","unstructured":"Knudsen HK, Roman PM. Service delivery and pharmacotherapy for alcohol use disorder in the era of health reform: Data from a national sample of treatment organizations. Subst Abus. 2016;37(1):230-237","journal-title":"Subst Abus."},{"issue":"4","key":"6073_CR10","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1176\/ps.2010.61.4.392","volume":"61","author":"AH Harris","year":"2010","unstructured":"Harris AH, Kivlahan DR, Bowe T, Humphreys KN. Pharmacotherapy of alcohol use disorders in the Veterans Health Administration. Psychiatr Serv. 2010; 61(4): 392-8","journal-title":"Psychiatr Serv."},{"issue":"5","key":"6073_CR11","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1046\/j.1360-0443.2003.00377.x","volume":"98","author":"TL Mark","year":"2003","unstructured":"Mark TL, Kranzler HR, Song X, Bransberger P, Poole VH, Crosse S. Physician\u2019s opinions about medications to treat alcoholism. Addiction. 2003; 98(5): 617-26.","journal-title":"Addiction."},{"issue":"6","key":"6073_CR12","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1097\/MLR.0000000000000918","volume":"56","author":"HA Huskamp","year":"2018","unstructured":"Huskamp HA, Riedel LE, Barry CL, Busch AB. Coverage of medications that treat opioid use disorder and opioids for pain management in Marketplace plans. Med Care. 2018;56(6):505-509.","journal-title":"Med Care."},{"key":"6073_CR13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jsat.2016.03.001","volume":"66","author":"S Reif","year":"2016","unstructured":"Reif S, Horgan CM, Hodgkin D, Matteucci AM, Creedon TB, Stewart MT. Access to Addiction Pharmacotherapy in Private Health Plans. J Subst Abuse Treat. 2016;66:23-29.","journal-title":"J Subst Abuse Treat."},{"issue":"2","key":"6073_CR14","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jsat.2007.02.004","volume":"34","author":"CM Horgan","year":"2008","unstructured":"Horgan CM, Reif S, Hodgkin D, Garnick DW, Merrick EL. Availability of addiction medications in private health plans. J Subst Abuse Treat. 2008;34(2):147-156.","journal-title":"J Subst Abuse Treat."},{"issue":"4","key":"6073_CR15","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1037\/a0030949","volume":"10","author":"AHS Harris","year":"2013","unstructured":"Harris AHS, Ellerbe L, Reeder RN, et al. Pharmacotherapy for alcohol dependence: perceived treatment barriers and action strategies among Veterans Health Administration service providers. Psychol Serv. 2013; 10(4): 410-419.","journal-title":"Psychol Serv."},{"issue":"4","key":"6073_CR16","doi-asserted-by":"publisher","first-page":"628","DOI":"10.15288\/jsad.2009.70.628","volume":"70","author":"AJ Abraham","year":"2009","unstructured":"Abraham AJ, Ducharme LJ, Roman PM. Counselor attitudes toward pharmacotherapies for alcohol dependence. J Stud Alcohol Drugs. 2009; 70(4): 628-35.","journal-title":"J Stud Alcohol Drugs."},{"issue":"11","key":"6073_CR17","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1377\/hlthaff.2013.0541","volume":"32","author":"MA Hoge","year":"2013","unstructured":"Hoge MA, Stuart GW, Morris J, Flaherty MT, Paris M, Jr., Goplerud E. Mental health and addiction workforce development: federal leadership is needed to address the growing crisis. Health Aff (Millwood). 2013;32(11):2005-2012.","journal-title":"Health Aff (Millwood)."},{"key":"6073_CR18","unstructured":"The American Psychiatric Association. Practice Guideline for the Pharmacological Treatment of Patients with Alcohol Use Disorder. Available at: https:\/\/psychiatryonline.org\/doi\/pdf\/10.1176\/appi.books.9781615371969. Accessed January 13, 2020."},{"issue":"4","key":"6073_CR19","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/ADM.0000000000000408","volume":"12","author":"CP Thomas","year":"2018","unstructured":"Thomas CP, Ritter GA, Harris AHS, Garnick DW, Freedman KI, Herbert B. Applying American Society of Addiction Medicine Performance Measures in Commercial Health Insurance and Services Data. J Addict Med. 2018;12(4):287-294.","journal-title":"J Addict Med."},{"key":"6073_CR20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1471-244X-11-41","volume":"11","author":"T Paparrigopoulos","year":"2011","unstructured":"Paparrigopoulos T, Tzavellas E, Karaiskos D, Kourlaba G, Liappas I. Treatment of alcohol dependence with low-dose topiramate: an open-label controlled study. BMC Psychiatry. 2011;11:41.","journal-title":"BMC Psychiatry."},{"issue":"14","key":"6073_CR21","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1001\/jama.298.14.1641","volume":"298","author":"BA Johnson","year":"2007","unstructured":"Johnson BA, Rosenthal N, Capece JA, et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA. 2007;298(14):1641-1651.","journal-title":"JAMA."},{"key":"6073_CR22","unstructured":"Department of Veterans Affairs, Department of Defense. VA\/DoD Clinical Practice Guideline for the Management of Substance Use Disorders. Version 3.0. Available at: https:\/\/www.healthquality.va.gov\/guidelines\/MH\/sud\/VADoDSUDCPGRevised22216.pdf. Accessed January 13, 2020."},{"key":"6073_CR23","unstructured":"Centers for Disease Control and Prevention. Alcohol and Public Health: Alcohol-Related Disease Impact (ARDI): Alcohol-Related ICD10 Codes. Available at: https:\/\/nccd.cdc.gov\/DPH_ARDI\/Info\/ICDCodes.aspx. Accessed September 23, 2019."},{"key":"6073_CR24","first-page":"CD004148","volume":"2","author":"EF Kaner","year":"2018","unstructured":"Kaner EF, Beyer FR, Muirhead C, et al. Effectiveness of brief alcohol interventions in primary care populations. Cochrane Database Syst Rev. 2018;2:CD004148.","journal-title":"Cochrane Database Syst Rev."},{"issue":"18","key":"6073_CR25","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1001\/jama.2018.12086","volume":"320","author":"EA O'Connor","year":"2018","unstructured":"O'Connor EA, Perdue LA, Senger CA, et al. Screening and Behavioral Counseling Interventions to Reduce Unhealthy Alcohol Use in Adolescents and Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2018;320(18):1910-1928.","journal-title":"JAMA."},{"issue":"18","key":"6073_CR26","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1001\/jama.2018.16789","volume":"320","author":"SJ Curry","year":"2018","unstructured":"Curry SJ, Krist AH, Owens DK, et al. Screening and Behavioral Counseling Interventions to Reduce Unhealthy Alcohol Use in Adolescents and Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;320(18):1899-1909.","journal-title":"JAMA."},{"key":"6073_CR27","unstructured":"University of New Mexico School of Medicine. About Echo. Available at: https:\/\/echo.unm.edu\/about-echo. Accessed September 23, 2019."},{"issue":"10","key":"6073_CR28","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1111\/j.1530-0277.2010.01267.x","volume":"34","author":"SF Greenfield","year":"2010","unstructured":"Greenfield SF, Pettinati HM, O'Malley S, Randall PK, Randall CL. Gender differences in alcohol treatment: an analysis of outcome from the COMBINE study. Alcohol Clin Exp Res. 2010;34(10):1803-12.","journal-title":"Alcohol Clin Exp Res."},{"key":"6073_CR29","doi-asserted-by":"crossref","unstructured":"Newberry S, Booth M, Rutter CM, et al. Gender Differences in Response to Alcohol Use Disorder Treatment: A Systematic Review. Santa Monica, CA: RAND Corporation, 2019. Available at: https:\/\/www.rand.org\/pubs\/research_reports\/RR2178.html. Accessed May 12, 2020.","DOI":"10.7249\/RR2178"},{"issue":"2","key":"6073_CR30","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1360-0443.2012.04054.x","volume":"108","author":"NC Maisel","year":"2013","unstructured":"Maisel NC, Blodgett JC, Wilbourne PL, Humphreys K, Finney JW. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction. 2013;108(2):275-293.","journal-title":"Addiction."},{"issue":"1","key":"6073_CR31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/0269881107078308","volume":"22","author":"S Rosner","year":"2008","unstructured":"Rosner S, Leucht S, Lehert P, Soyka M. Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes. J Psychopharmacol. 2008;22(1):11-23.","journal-title":"J Psychopharmacol."}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-020-06073-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-020-06073-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-020-06073-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T00:04:21Z","timestamp":1628035461000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-020-06073-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,4]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["6073"],"URL":"https:\/\/doi.org\/10.1007\/s11606-020-06073-w","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,4]]},"assertion":[{"value":"14 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they do not have a conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}